• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丁丙诺啡可能并不像你想象的那么安全:一起儿童意外暴露致死案例。

Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.

机构信息

New York University Langone Medical Center/Bellevue Hospital Center, New York City Poison Control Center, New York, NY 10016, USA.

出版信息

Pediatrics. 2012 Dec;130(6):e1700-3. doi: 10.1542/peds.2012-1342. Epub 2012 Nov 5.

DOI:10.1542/peds.2012-1342
PMID:23129079
Abstract

Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use buprenorphine, an increasing number of children are being exposed. We report a fatal exposure to buprenorphine in a small child that occurred after ingestion of a caretaker's buprenorphine/naloxone. Postmortem toxicology analysis showed free serum concentrations of 52 ng/mL and 39 ng/mL for buprenorphine and norbuprenorphine, respectively. No other drugs were detected. Autopsy did not find signs of injury or trauma. The theoretical safety provided by the ceiling effect in respiratory depression from buprenorphine may not apply to children, and buprenorphine may cause dose-dependent respiratory depression.

摘要

丁丙诺啡是一种部分μ-阿片受体激动剂,已被批准用于治疗阿片类药物依赖。由于其对呼吸抑制的封顶效应,一般认为它比美沙酮更安全。随着越来越多的美国家庭成年人使用丁丙诺啡,越来越多的儿童受到暴露。我们报告了一例因摄入看护者的丁丙诺啡/纳洛酮而导致的幼儿致命暴露于丁丙诺啡的病例。尸检毒理学分析显示,丁丙诺啡和去甲丁丙诺啡的游离血清浓度分别为 52ng/mL 和 39ng/mL。未检测到其他药物。尸检未发现损伤或创伤的迹象。丁丙诺啡在呼吸抑制方面提供的封顶效应的理论安全性可能不适用于儿童,并且丁丙诺啡可能会导致剂量依赖性呼吸抑制。

相似文献

1
Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.丁丙诺啡可能并不像你想象的那么安全:一起儿童意外暴露致死案例。
Pediatrics. 2012 Dec;130(6):e1700-3. doi: 10.1542/peds.2012-1342. Epub 2012 Nov 5.
2
Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.在家中接触丁丙诺啡/纳洛酮后需要入住儿科重症监护病房的幼儿。
Pediatr Crit Care Med. 2011 Mar;12(2):e102-7. doi: 10.1097/PCC.0b013e3181f3a118.
3
Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.肠外滥用丁丙诺啡-纳洛酮是导致致命丁丙诺啡相关中毒的主要原因。
Forensic Sci Int. 2013 Oct 10;232(1-3):11-5. doi: 10.1016/j.forsciint.2013.06.017. Epub 2013 Jul 19.
4
Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report.儿童患者中丁丙诺啡/纳洛酮复合制剂(舒泊西酮)中毒:一例报告
Pediatr Emerg Care. 2007 Sep;23(9):651-2. doi: 10.1097/PEC.0b013e31814a6aac.
5
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.达芦那韦/利托那韦与使用美沙酮或丁丙诺啡/纳洛酮的阿片类维持治疗之间的药代动力学相互作用。
J Clin Pharmacol. 2011 Feb;51(2):271-8. doi: 10.1177/0091270010365558. Epub 2010 Apr 26.
6
Adverse effects in children after unintentional buprenorphine exposure.儿童意外暴露于丁丙诺啡后的不良反应。
Pediatrics. 2006 Oct;118(4):1746-51. doi: 10.1542/peds.2006-0948.
7
Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.在接受慢性丁丙诺啡/纳洛酮治疗的受试者中,丁丙诺啡/纳洛酮与雷特格韦的药代动力学相互作用。
Am J Drug Alcohol Abuse. 2013 Mar;39(2):80-5. doi: 10.3109/00952990.2013.764885.
8
Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.剂量递增试验中多次舌下含服丁丙诺啡片的药代动力学和药效学
J Clin Pharmacol. 2006 Feb;46(2):179-92. doi: 10.1177/0091270005284192.
9
In-vitro and in-vivo characterization of a buprenorphine delivery system.丁丙诺啡给药系统的体外和体内特性研究
J Pharm Pharmacol. 2006 Mar;58(3):295-302. doi: 10.1211/jpp.58.3.0002.
10
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.基于机制的纳洛酮逆转丁丙诺啡所致呼吸抑制的药代动力学-药效学建模:一项在健康志愿者中的研究
Clin Pharmacokinet. 2007;46(11):965-80. doi: 10.2165/00003088-200746110-00004.

引用本文的文献

1
An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.非选择性阿片类调制药物丁丙诺啡的复杂药理特性研究
Pharmaceuticals (Basel). 2023 Oct 2;16(10):1397. doi: 10.3390/ph16101397.
2
Assessment of the potential of novel and classical opioids to induce respiratory depression in mice.评估新型和经典阿片类药物在小鼠中引起呼吸抑制的潜力。
Br J Pharmacol. 2023 Dec;180(24):3160-3174. doi: 10.1111/bph.16199. Epub 2023 Aug 22.
3
Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.
注意差距:人类大脑 P-糖蛋白的个体发生及其对药物毒性的影响。
AAPS J. 2019 May 28;21(4):67. doi: 10.1208/s12248-019-0340-z.
4
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.阿片类物质使用障碍的药物治疗:药物疗法、辅助治疗及毒性综述
J Med Toxicol. 2018 Dec;14(4):306-322. doi: 10.1007/s13181-018-0685-1. Epub 2018 Oct 30.
5
Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.美沙酮治疗青少年和年轻成人阿片类药物使用障碍:叙述性综述。
J Addict Med. 2018 May/Jun;12(3):170-183. doi: 10.1097/ADM.0000000000000388.
6
Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.妊娠通过诱导肝脏葡萄糖醛酸化增加小鼠中诺布啡的清除率。
Drug Metab Dispos. 2018 Feb;46(2):100-108. doi: 10.1124/dmd.117.076745. Epub 2017 Nov 20.
7
P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.P-糖蛋白/ABCB1对脑和胎儿接触诺布普诺啡有不同影响。
Pharmacol Res. 2017 May;119:61-71. doi: 10.1016/j.phrs.2017.01.018. Epub 2017 Jan 19.
8
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?美国政府应该废除对丁丙诺啡/纳洛酮治疗的限制吗?
Subst Use Misuse. 2016 Oct 14;51(12):1674-1679. doi: 10.1080/10826084.2016.1200097. Epub 2016 Jul 27.
9
The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.新成员——将丁丙诺啡纳入医学毒理学实践
J Med Toxicol. 2016 Mar;12(1):64-70. doi: 10.1007/s13181-015-0518-4.
10
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.与阿片类物质使用障碍的阿片类激动剂治疗相关的政策:2004年至2013年各州政策的演变
Subst Abus. 2016;37(1):63-9. doi: 10.1080/08897077.2015.1080208. Epub 2015 Nov 13.